Arthritis Rheumatol
ACR 2025: TYK2 inhibitor demonstrates lasting improvements in psoriatic arthritis
Presented at ACR Convergence, this phase 3 study showed that deucravacitinib, a selective TYK2 inhibitor, provided durable clinical benefit and was well tolerated through 52 weeks in patients with active psoriatic arthritis (PsA) who were biologic-naive.
Study details: In the global, double-blind POETYK PsA-1 trial (NCT04908202), 670 patients with active PsA were randomized 1:1 to receive deucravacitinib 6 mg daily or placebo for 16 weeks. At week 16, placebo patients switched to deucravacitinib through week 52. Key endpoints included American College of Rheumatology (ACR) responses, radiographic progression, and patient-reported outcomes (PROs). Safety was assessed throughout.
Results: The primary endpoint (ACR 20 at week 16) was met (P<0.0001), with continued improvement through week 24 and sustained responses through week 52. ACR 50/70, PROs, and inhibition of radiographic progression were also maintained. Patients switching from placebo at week 16 showed reduced radiographic progression thereafter. Deucravacitinib was well tolerated, with few serious adverse events and no new safety signals.
Source:
van der Heijde D, et al. “Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs” [abstract]. Arthritis Rheumatol. https://acrabstracts.org/abstract/efficacy-and-safety-of-deucravacitinib-up-to-week-52-a-multicenter-randomized-double-blind-placebo-controlled-phase-3-study-in-patients-with-active-psoriatic-arthritis-who-are-naive-to-biologic-d/. Accessed October 31, 2025.